SwePub
Sök i SwePub databas

  form:Ext_t

Träfflista för sökning "WFRF:(Matsuo K) "

form:Search_simp_t: WFRF:(Matsuo K)

  • navigation:Result_t 1-10 navigation:of_t 141
hitlist:Modify_result_t
   
hitlist:Enumeration_thitlist:Reference_thitlist:Reference_picture_thitlist:Find_Mark_t
1.
  • 2017
  • swepub:Mat__t
  •  
2.
  •  
3.
  • Namkoong, H, et al. (creator_code:aut_t)
  • DOCK2 is involved in the host genetics and biology of severe COVID-19
  • 2022
  • record:In_t: Nature. - : Springer Science and Business Media LLC. - 1476-4687 .- 0028-0836. ; 609:7928, s. 754-
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • Identifying the host genetic factors underlying severe COVID-19 is an emerging challenge1–5. Here we conducted a genome-wide association study (GWAS) involving 2,393 cases of COVID-19 in a cohort of Japanese individuals collected during the initial waves of the pandemic, with 3,289 unaffected controls. We identified a variant on chromosome 5 at 5q35 (rs60200309-A), close to the dedicator of cytokinesis 2 gene (DOCK2), which was associated with severe COVID-19 in patients less than 65 years of age. This risk allele was prevalent in East Asian individuals but rare in Europeans, highlighting the value of genome-wide association studies in non-European populations. RNA-sequencing analysis of 473 bulk peripheral blood samples identified decreased expression of DOCK2 associated with the risk allele in these younger patients. DOCK2 expression was suppressed in patients with severe cases of COVID-19. Single-cell RNA-sequencing analysis (n = 61 individuals) identified cell-type-specific downregulation of DOCK2 and a COVID-19-specific decreasing effect of the risk allele on DOCK2 expression in non-classical monocytes. Immunohistochemistry of lung specimens from patients with severe COVID-19 pneumonia showed suppressed DOCK2 expression. Moreover, inhibition of DOCK2 function with CPYPP increased the severity of pneumonia in a Syrian hamster model of SARS-CoV-2 infection, characterized by weight loss, lung oedema, enhanced viral loads, impaired macrophage recruitment and dysregulated type I interferon responses. We conclude that DOCK2 has an important role in the host immune response to SARS-CoV-2 infection and the development of severe COVID-19, and could be further explored as a potential biomarker and/or therapeutic target.
  •  
4.
  • Ruilope, LM, et al. (creator_code:aut_t)
  • Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial
  • 2019
  • record:In_t: American journal of nephrology. - : S. Karger AG. - 1421-9670 .- 0250-8095. ; 50:5, s. 345-356
  • swepub:Mat_article_t (swepub:level_refereed_t)abstract
    • <b><i>Background:</i></b> Among people with diabetes, those with kidney disease have exceptionally high rates of cardiovascular (CV) morbidity and mortality and progression of their underlying kidney disease. Finerenone is a novel, nonsteroidal, selective mineralocorticoid receptor antagonist that has shown to reduce albuminuria in type 2 diabetes (T2D) patients with chronic kidney disease (CKD) while revealing only a low risk of hyperkalemia. However, the effect of finerenone on CV and renal outcomes has not yet been investigated in long-term trials. <b><i>Patients and</i></b> <b><i>Methods:</i></b> The Finerenone in Reducing CV Mortality and Morbidity in Diabetic Kidney Disease (FIGARO-DKD) trial aims to assess the efficacy and safety of finerenone compared to placebo at reducing clinically important CV and renal outcomes in T2D patients with CKD. FIGARO-DKD is a randomized, double-blind, placebo-controlled, parallel-group, event-driven trial running in 47 countries with an expected duration of approximately 6 years. FIGARO-DKD randomized 7,437 patients with an estimated glomerular filtration rate ≥25 mL/min/1.73 m<sup>2</sup> and albuminuria (urinary albumin-to-creatinine ratio ≥30 to ≤5,000 mg/g). The study has at least 90% power to detect a 20% reduction in the risk of the primary outcome (overall two-sided significance level α = 0.05), the composite of time to first occurrence of CV death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure. <b><i>Conclusions:</i></b> FIGARO-DKD will determine whether an optimally treated cohort of T2D patients with CKD at high risk of CV and renal events will experience cardiorenal benefits with the addition of finerenone to their treatment regimen. Trial Registration: EudraCT number: 2015-000950-39; ClinicalTrials.gov identifier: NCT02545049.
  •  
5.
  •  
6.
  • Klionsky, Daniel J., et al. (creator_code:aut_t)
  • Guidelines for the use and interpretation of assays for monitoring autophagy
  • 2012
  • record:In_t: Autophagy. - : Informa UK Limited. - 1554-8635 .- 1554-8627. ; 8:4, s. 445-544
  • swepub:Mat_researchreview_t (swepub:level_refereed_t)abstract
    • In 2008 we published the first set of guidelines for standardizing research in autophagy. Since then, research on this topic has continued to accelerate, and many new scientists have entered the field. Our knowledge base and relevant new technologies have also been expanding. Accordingly, it is important to update these guidelines for monitoring autophagy in different organisms. Various reviews have described the range of assays that have been used for this purpose. Nevertheless, there continues to be confusion regarding acceptable methods to measure autophagy, especially in multicellular eukaryotes. A key point that needs to be emphasized is that there is a difference between measurements that monitor the numbers or volume of autophagic elements (e.g., autophagosomes or autolysosomes) at any stage of the autophagic process vs. those that measure flux through the autophagy pathway (i.e., the complete process); thus, a block in macroautophagy that results in autophagosome accumulation needs to be differentiated from stimuli that result in increased autophagic activity, defined as increased autophagy induction coupled with increased delivery to, and degradation within, lysosomes (in most higher eukaryotes and some protists such as Dictyostelium) or the vacuole (in plants and fungi). In other words, it is especially important that investigators new to the field understand that the appearance of more autophagosomes does not necessarily equate with more autophagy. In fact, in many cases, autophagosomes accumulate because of a block in trafficking to lysosomes without a concomitant change in autophagosome biogenesis, whereas an increase in autolysosomes may reflect a reduction in degradative activity. Here, we present a set of guidelines for the selection and interpretation of methods for use by investigators who aim to examine macroautophagy and related processes, as well as for reviewers who need to provide realistic and reasonable critiques of papers that are focused on these processes. These guidelines are not meant to be a formulaic set of rules, because the appropriate assays depend in part on the question being asked and the system being used. In addition, we emphasize that no individual assay is guaranteed to be the most appropriate one in every situation, and we strongly recommend the use of multiple assays to monitor autophagy. In these guidelines, we consider these various methods of assessing autophagy and what information can, or cannot, be obtained from them. Finally, by discussing the merits and limits of particular autophagy assays, we hope to encourage technical innovation in the field.
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • navigation:Result_t 1-10 navigation:of_t 141
swepub:Mat_t
swepub:mat_article_t (136)
swepub:mat_researchreview_t (2)
swepub:mat_publicationother_t (1)
swepub:mat_conferencepaper_t (1)
swepub:Level_t
swepub:level_refereed_t (135)
swepub:level_scientificother_t (5)
swepub:Hitlist_author_t
Matsuo, K (71)
Teo, SH (52)
Zheng, W. (50)
Fasching, PA (48)
Chang-Claude, J (47)
Nevanlinna, H (47)
deldatabas:search_more_t
Kang, D. (46)
Shu, XO (46)
Hall, P (45)
Lambrechts, D (45)
Dennis, J (44)
Giles, GG (44)
Bolla, MK (44)
Beckmann, MW (44)
Shen, CY (44)
Couch, FJ (44)
Southey, MC (43)
Hamann, U (43)
Garcia-Closas, M (43)
Jakubowska, A (43)
Ito, H. (42)
Hartman, M (42)
Dunning, AM (42)
Chenevix-Trench, G (42)
Wang, Q. (41)
Andrulis, IL (41)
Schmidt, MK (41)
Wu, AH (41)
Haiman, CA (41)
Dork, T (41)
Czene, K (40)
Anton-Culver, H (40)
Hopper, JL (40)
Bojesen, SE (40)
Brenner, H (39)
Milne, RL (39)
Lubinski, J (39)
Benitez, J. (38)
Guenel, P (38)
Mannermaa, A (38)
Winqvist, R (38)
Lindblom, A (37)
Margolin, S (37)
Choi, JY (37)
Muir, K (37)
Truong, T (37)
Simard, J (37)
Cox, A (36)
Lophatananon, A (36)
Devilee, P (36)
deldatabas:search_less_t
swepub:Hitlist_uni_t
swepub_uni:ki_t (94)
swepub_uni:uu_t (28)
swepub_uni:lu_t (22)
swepub_uni:su_t (12)
swepub_uni:umu_t (11)
swepub_uni:gu_t (7)
deldatabas:search_more_t
swepub_uni:cth_t (6)
swepub_uni:oru_t (1)
swepub_uni:lnu_t (1)
swepub_uni:ri_t (1)
swepub_uni:slu_t (1)
deldatabas:search_less_t
hitlist:Language_t
language:Eng_t (141)
hitlist:HSV_t
hsv:Cat_3_t (47)
hsv:Cat_1_t (28)
hsv:Cat_2_t (1)

hitlist:Year_t

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt tools:Close_t

tools:Permalink_label_t